Recipharm AB and Medspray BV, a manufacturer of high tech spray nozzles, have established a joint venture known as Resyca BV to develop and exploit the softmist spray nozzle technology for pharmaceutical applications. Recipharm will invest €15 million in return for 51% of the shares of Resyca. Medspray will transfer their softmist intellectual property relating to pharmaceutical applications into Resyca. The technology has the potential to eliminate the need for propellants by delivering therapies deep into the lungs more effectively with lower doses as less ends up in the mouth and throat.
Resyca will operate development facilities in Munich, Germany and spray nozzles will be supplied exclusively from Medspray in the Netherlands. The JV anticipates that commercial supply of finished devices will be manufactured and supplied by other Recipharm affiliates including the specialist device manufacturing capabilities located in King’s Lynn, UK.
Additionally, Recipharm will receive an exclusive license to offer its customers the development and manufacturing of syringe-based devices using the softmist nozzle technology. Such devices will be marketed by Recipharm under the brand, Bespak by Recipharm.